Recently, it was also approved for the treatment of metastatic colorectal cancer and renal cell carcinoma in combination with anti-PD-1-blocking antibody, i.e., Nivolumab [222]. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.